2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1572

High Type I Interferon In Systemic Lupus Erythematosus Plasma Predicts Future Renal Disease
Abstract Number: 1892

High-Throughput Immunoglobulin G Fab Glycosylation Profiling Reveals Differential Glycosylation On Fab and Fc
Abstract Number: 93

Higher Consumption Of Sugar-Sweetened Soft Drinks Increases The Risk Of Hyperuricemia In Korean Population: The Korean Multi-Rural Communities Cohort Study
Abstract Number: 2870

Higher Disease Activity and Serum Levels Of Angiogenic Factors In Patients With Rheumatoid Arthritis In Clinical Remission With Synovitis On Ultrasound
Abstract Number: 300

Higher Disease Activity In Psoriatic Arthritis Is Associated With Elevated Total Cholesterol and Triglycerides
Abstract Number: 2837

Higher Disease Activity Leads To More Damage In The Early Phases Of Ankylosing Spondylitis: 12-Year Data From The OASIS Cohort
Abstract Number: 2505

Higher Disease Damage Among African Americans With Familial Versus Sporadic Systemic Lupus Erythematosus
Abstract Number: 253

Higher Leg Extensor Muscle Power Output Is Associated With Reduced Pain and Better Quality Of Life In Patients With Symptomatic Knee Osteoarthritis
Abstract Number: 2119

Higher Mortality In Males Compared To Females Undergoing Total Knee Or Total Hip Arthroplasty: A Study Of National Time Trends, 2003-2010
Abstract Number: 465

Higher Titer Of Anti-Citrullinated Protein Antibodies In Biologic-Naïve Rheumatoid Arthritis Patients Are Candidate Biomarkers To Predict Sensitivity Leading To Clinical Remission With Abatacept; Data From The Abroad Study
Abstract Number: 461

Higher TNFi Dosing Is Not Associated With More Serious Infectious Events (SIE), Elevated AST/ALT Or WBC<1.5 In The US Corrona Database
Abstract Number: 2112

Hip and Knee Arthroplasty In Patients With Rheumatoid Arthritis: Results From The Australian Orthopaedic Association National Joint Replacement Registry: 2003 To 2011
Abstract Number: 236

Hip Bone Marrow Lesions In Asymptomatic and Osteoarthritic Adults: Prevalence, Risk Factors and Significance
Abstract Number: 2114

Hip Fracture Risk Factors To One Year and In-Hospital Mortality , a Prospective Cohort In South Brazil
Abstract Number: 95

Hip Osteoarthritis and Risk Of All Cause and Disease-Specific Mortality Among Older Women: A Population-Based Cohort Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].